GLP 1 Receptor Agonists for Weight Control: Emerging Insights from Clinical Trials and Future Perspectives Mazdutide 5mg Dosage Protocol PeptideDosages.com Efficacy and safety of incretin co agonists: Transformative advances in cardiometabolic healthcare In Chinese adults with overweight or obesity, once weekly #GLP glucagon agonist mazdutide, at a dose of 4 mg or 6 mg for 32 48 weeks, led to clinically relevant #weightloss in the Once weekly mazdutide, a glucagon like peptide 1 and glucagon receptor dual agonist, provided clinically relevant reduction in body weight in Chinese adults with obesity or overweight. Full GLORY 1 trial results: https: nej.md 4koUvaP GLP 1 receptor agonists and next generation incretin based medications: metabolic, cardiovascular, and renal benefits The Lancet